Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Irinotecan × CNS × Clear all

Phase

Phase 2 50 Phase 1 30 Phase 1/2 18 Phase EARLY_PHASE1 4 Phase 3 2 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 13 Thoracic 1 Sarcoma 1 CNS 1

Conditions

Interventions

Temozolomide 10 Lomustine 6 Radiotherapy 4 Etoposide 3 Carboplatin 3 Bevacizumab 3 vocimagene amiretrorepvec 2 Vincristine 2 Radiation 2 Magnetic Resonance Spectroscopy 2 Gefitinib 2 veliparib 1 trofosfamide 1 trametinib 1 tozuleristide 1 regorafenib 1 dabrafenib 1 cobimetinib 1 carbon-11 acetate 1 antisecretory factor 1 Vorinostat 1 Vemurafenib 1 Thiotepa 1 Sunitinib 1 Standard of Care 1 Saline Solution 1 Procarbazine 1 Pregabalin 1 Minocycline 1 Melphalan 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01308632 2011-03-04

Metronomic Temozolamide in Patients With Recurrent Glioblastoma

Grupo Español de Investigación en Neurooncología

Phase 2/3 Unknown

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡